Senzime ABFRA:6YC 57 PB Ratio is 2.05 as of Jul. 05, 2026, which is 19% below its 10-year median of 2.54. GuruFocus rates FRA:6YC with a GF Score™ of 57/100 and a GF Value™ of €0.85 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 788 Medical Devices & Instruments companies, Senzime AB ranks worse than 54.7% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-05), Senzime AB's share price is €0.342. Senzime AB's Book Value per Share for the quarter that ended in Mar. 2026 was €0.17. Hence, Senzime AB's PB Ratio of today is 2.05.
The historical rank and industry rank for Senzime AB's PB Ratio or its related term are showing as below:
FRA:6YC'
s PB Ratio Range Over the Past 10 Years
Min: 0.79 Med: 2.54 Max: 10
Current: 2.38
During the past 13 years, Senzime AB's highest PB Ratio was 10.00. The lowest was 0.79. And the median was 2.54.
FRA:6YC's PB Ratio is ranked worse than 54.7% of 788
companies
in the Medical Devices & Instruments industry
Industry Median: 2.07
vs FRA:6YC: 2.38
During the past 12 months, Senzime AB's average Book Value Per Share Growth Rate was -21.50% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -19.40% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -8.40% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -0.40% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Senzime AB was 21.50% per year. The lowest was -19.40% per year. And the median was -1.35% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Senzime AB PB Ratio Related Terms
Senzime AB PB Ratio Historical Data
* Premium members only.
The historical data trend for Senzime AB's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Senzime AB's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Senzime AB PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Senzime AB's PB Ratio distribution charts can be found below:
* The bar in red indicates where Senzime AB's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Senzime AB's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Senzime AB (FRA:6YC) has a PB Ratio of 2.05 as of Jul. 05, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Senzime AB and its competitors. This is 19% below median its historical median of 2.54. Over the past decade, Senzime AB's PB Ratio has ranged from 0.79 to 10.00. According to the industry distribution chart, Senzime AB ranks #431 out of 788 companies in the Medical Devices & Instruments industry, placing it in the top 54.7%.
Is Senzime AB's PB Ratio too high?
Senzime AB's current PB Ratio of 2.05 is 19% below median its 10-year median of 2.54. Over the past 10 years, this metric has ranged from a low of 0.79 to a high of 10.00. The Medical Devices & Instruments industry median PB Ratio is 2.07. Senzime AB's value of 2.05 is 1% below this industry median. Based on the distribution chart, Senzime AB ranks #431 out of 788 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Senzime AB has a GF Score™ of 57/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Senzime AB's PB Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Senzime AB ranks #431 out of 788 companies for PB Ratio. This places Senzime AB in the lower half of its industry. The industry median PB Ratio is 2.07. Senzime AB's value of 2.05 is 1% below this benchmark. Historically, Senzime AB's own PB Ratio has ranged from 0.79 to 10.00 over the past decade. While the company's 10-year median is 2.54 vs. the industry median of 2.07, Senzime AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.07, based on 788 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Senzime AB's current PB Ratio of 2.05 is 1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Senzime AB and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Senzime AB's current PB Ratio is 2.05, which is 19% below median its own 10-year median of 2.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Senzime AB stock overvalued right now?
Based on GuruFocus' analysis, Senzime AB (FRA:6YC) is currently considered Possible Value Trap. The stock's GF Value™ is €0.85, compared to a current price of €0.34 — trading 59.8% below its estimated fair value. The current PB Ratio is 2.05, which is 19% below median its 10-year median of 2.54 and 1% below the Medical Devices & Instruments industry median of 2.07. Senzime AB's overall GF Score™ is 57/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Senzime AB (FRA:6YC), the current PB Ratio is 2.05 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Senzime AB (FRA:6YC) Overvalued in 2026?
Based on GuruFocus' analysis, Senzime AB stock appears to be undervalued.
The current stock price of €0.34 is trading 59.8% below its estimated GF Value™ of €0.85.
GuruFocus considers Senzime AB to be Possible Value Trap.
Key valuation signals for FRA:6YC:
PB Ratio: 2.05 (19% below median its 10-year median of 2.54)
GF Value™: €0.85 vs. price of €0.34 (59.8% below fair value)
Industry Position: 1% below the Medical Devices & Instruments median (#431 of 788)
No single metric tells the full story. See the FRA:6YC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Senzime AB is a medical device company developing precision-based patient monitoring solutions for patients undergoing anesthesia. The company develops and markets precision-based monitoring systems for monitoring neuromuscular function and respiration during and after surgery, as well as for intensive care. Its product portfolio includes Next-generation TetraGraph, TetraGraph connectivity, TetraGraph for pediatric, Classic TetraGraph, and ExSpiron. The TetraGraph system is used in thousands of operating rooms internationally in university hospitals, public, private, military, and veterans hospitals. Senzime has direct sales resources in the USA and Germany and collaborates with distributors and licensees in its other main markets.
57GF Score
Get the complete analysis for FRA:6YC
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6YC has been successfully added to your 
